Affinity Asset Advisors
SPRO icon

Affinity Asset Advisors’s Spero Therapeutics SPRO Stock Holding History

Affinity Asset Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.57M Buy
+1,300,000
New +$1.76M 0.06% 112

Other funds holding SPRO

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Affinity Asset Advisors's SPRO Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Spero Therapeutics (SPRO) in Q3 2026: 1,300,000 shares worth $1.57M. The stake represents 0.06% of the portfolio and ranks #112 among its holdings.

43 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

  • Affinity Asset Advisors held 1,300,000 shares of Spero Therapeutics worth $1.57M as of Q3 2026.
  • Spero Therapeutics was a new Affinity Asset Advisors position in Q3 2026.
  • Spero Therapeutics made up 0.06% of Affinity Asset Advisors's portfolio in Q3 2026, its #112 holding.
  • 43 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.